| General Information | |
|---|---|
| ZINC ID | ZINC000043018882 |
| Molecular Weight (Da) | 500 |
| SMILES | Clc1ccc(C[C@H](CNc2cc(NC3CCCCC3)ncn2)c2cccc(Br)c2)cc1 |
| Molecular Formula | C25Br1Cl1N4 |
| Action | Antagonist |
| Physicochemical Details | |
|---|---|
| Molar Refractivity | 135.745 |
| HBA | 2 |
| HBD | 2 |
| Rotatable Bonds | 8 |
| Heavy Atoms | 31 |
| LogP | 7.736 |
| Activity (Ki) in nM | 812.831 |
| Polar Surface Area (PSA) | 49.84 |
| Pharmacokinetic Properties (AdmetSAR) | |
|---|---|
| Human intestinal absorption | + |
| Caco-2 | - |
| Blood brain barrier | + |
| P-glycoprotein inhibitior | + |
| P-glycoprotein substrate | - |
| Cyp3a4 substrate | + |
| Cyp2c9 substrate | - |
| Cyp2d6 substrate | - |
| Cyp3a4 inhibition | - |
| Cyp2c9 inhibition | - |
| Cyp2c19 inhibition | - |
| Cyp2d6 inhibition | + |
| Cyp1a2 inhibition | + |
| Acute oral toxicity | - |
| Carcinogenicity (binary) | - |
| Ames mutagenesis | - |
| Human ether-a-go-go-related gene inhibition | + |
| Biodegradation | - |
| Glucocorticoid receptor binding | + |
| Thyroid receptor binding | + |
| Androgen receptor binding | + |
| Plasma protein binding | 1.11041891 |
| Pharmacokinetic Properties (SwissADME) | |
|---|---|
| Number of aromatic heavy atoms | 18 |
| Fraction csp3 | 0.36 |
| Ilogp | 4.67 |
| Xlogp3 | 7.67 |
| Wlogp | 6.69 |
| Mlogp | 5.37 |
| Silicos-it log p | 6.18 |
| Consensus log p | 6.12 |
| Esol log s | -7.67 |
| Esol solubility (mg/ml) | 0.0000106 |
| Esol solubility (mol/l) | 2.12E-08 |
| Esol class | Poorly sol |
| Ali log s | -8.56 |
| Ali solubility (mg/ml) | 0.00000139 |
| Ali solubility (mol/l) | 2.77E-09 |
| Ali class | Poorly sol |
| Silicos-it logsw | -10.37 |
| Silicos-it solubility (mg/ml) | 2.11E-08 |
| Silicos-it solubility (mol/l) | 4.23E-11 |
| Silicos-it class | Insoluble |
| Pgp substrate | |
| Log kp (cm/s) | -3.9 |
| Lipinski number of violations | 1 |
| Ghose number of violations | 3 |
| Veber number of violations | 0 |
| Egan number of violations | 1 |
| Muegge number of violations | 1 |
| Bioavailability score | 0.55 |
| Pains number of alerts | 0 |
| Brenk number of alerts | 0 |
| Leadlikeness number of violations | 3 |
| Synthetic accessibility | 3.69 |
| Pharmacokinetic Properties (ADMETLab) | |
|---|---|
| Logs | -5.029 |
| Logd | 4.698 |
| Logp | 6.558 |
| F (20%) | 0.013 |
| F (30%) | 0.956 |
| Mdck | - |
| Ppb | 98.14% |
| Vdss | 2.744 |
| Fu | 0.77% |
| Cyp1a2-inh | 0.946 |
| Cyp1a2-sub | 0.175 |
| Cyp2c19-inh | 0.94 |
| Cyp2c19-sub | 0.07 |
| Cl | 4.588 |
| T12 | 0.03 |
| H-ht | 0.578 |
| Dili | 0.626 |
| Roa | 0.872 |
| Fdamdd | 0.963 |
| Skinsen | 0.669 |
| Ec | 0.003 |
| Ei | 0.054 |
| Respiratory | 0.922 |
| Bcf | 2.525 |
| Igc50 | 5.275 |
| Lc50 | 6.516 |
| Lc50dm | 6.465 |
| Nr-ar | 0.021 |
| Nr-ar-lbd | 0.002 |
| Nr-ahr | 0.911 |
| Nr-aromatase | 0.942 |
| Nr-er | 0.352 |
| Nr-er-lbd | 0.003 |
| Nr-ppar-gamma | 0.012 |
| Sr-are | 0.494 |
| Sr-atad5 | 0.567 |
| Sr-hse | 0.889 |
| Sr-mmp | 0.897 |
| Sr-p53 | 0.642 |
| Vol | 461.484 |
| Dense | 1.079 |
| Flex | 0.28 |
| Nstereo | 1 |
| Nongenotoxic carcinogenicity | 1 |
| Ld50 oral | 0 |
| Genotoxic carcinogenicity mutagenicity | 1 |
| Surechembl | 0 |
| Nonbiodegradable | 1 |
| Skin sensitization | 2 |
| Acute aquatic toxicity | - |
| Toxicophores | 0 |
| Qed | 0.39 |
| Synth | 3.477 |
| Fsp3 | 0.36 |
| Mce-18 | 67.059 |
| Natural product-likeness | -0.593 |
| Alarm nmr | 2 |
| Bms | 0 |
| Chelating | 0 |
| Pfizer | - |
| Gsk | Rejected |
| Goldentriangle | Accepted |